In patients with new-onset T2D, early statin initiation is associated with worse short-term glycemic improvement and a greater need for escalating glucose-lowering therapy; however, it is also associated with a substantial reduction in the long-term MACE risk.
Key Findings
Results
At 6-month follow-up, statin therapy significantly attenuated glycemic improvement in HbA1c, fasting plasma glucose, and 2-hour post-prandial glucose levels compared to the nonstatin group.
Both groups exhibited improved glycemic indices at 6 months, but improvement was significantly attenuated in the statin group.
Group × time interaction effects were statistically significant for FPG, 2hPG, and HbA1c levels at 6 months.
Longitudinal glycemic trajectories were assessed using two-way repeated-measures ANOVA.
The study enrolled 604 eligible patients: statin group (n = 458) and nonstatin group (n = 146).
Results
By 60 months of follow-up, between-group differences in HbA1c levels were no longer statistically significant.
The attenuation of glycemic improvement observed at 6 months in the statin group did not persist to the 60-month timepoint.
This suggests the short-term adverse glycemic effect of statins may diminish over longer follow-up.
Patients were newly diagnosed with T2D between January 2018 and December 2020.
Results
Statin therapy was associated with higher frequencies of diabetes therapy intensification, insulin initiation, and hyperglycemic crisis over a median follow-up of 73 months.
Diabetes therapy intensification occurred in 33.3% of the statin group vs. 22.6% of the nonstatin group (p = 0.016).
Insulin initiation occurred in 21.5% of the statin group vs. 12.3% of the nonstatin group (p = 0.015).
Hyperglycemic crisis occurred in 8.5% of the statin group vs. 3.4% of the nonstatin group (p = 0.039).
Median (interquartile range) follow-up was 73 (68–80) months.
Results
Despite metabolic disadvantages, statin therapy was independently associated with a substantially lower risk of major adverse cardiovascular events (MACEs).
Multivariable Cox regression analysis showed statin therapy was associated with a lower MACE risk (HR 0.41, 95% CI 0.21–0.83; p = 0.013).
MACE risk was also evaluated using Kaplan-Meier analysis.
The hazard ratio of 0.41 indicates approximately a 59% relative reduction in MACE risk associated with statin therapy.
This cardiovascular benefit persisted despite the observed short-term worsening of glycemic control.
Methods
The study population consisted of patients newly diagnosed with type 2 diabetes who were screened between January 2018 and December 2020, with 604 ultimately classified into statin and nonstatin groups.
This was a retrospective cohort study design.
The statin group comprised 458 patients and the nonstatin group comprised 146 patients.
Primary outcome was change in HbA1c levels; secondary outcomes included FPG, 2hPG, diabetes therapy intensification, insulin initiation, hyperglycemic crisis, and MACEs.
The study focused specifically on patients with new-onset (newly diagnosed) T2D to examine effects of early statin initiation.
What This Means
This research suggests that for people newly diagnosed with type 2 diabetes, starting statin medications (commonly prescribed to lower cholesterol and reduce heart disease risk) comes with a trade-off. In the short term—around 6 months after starting the medication—people taking statins did not see as much improvement in their blood sugar levels as those not taking statins. They were also more likely to need stronger diabetes medications, more likely to require insulin, and more likely to experience dangerous episodes of very high blood sugar over a follow-up period of about 6 years.
However, despite these blood sugar-related drawbacks, people who took statins had a substantially lower risk of major cardiovascular events such as heart attacks or strokes. Specifically, statin users had about 59% lower risk of these serious heart-related events compared to non-users, even after accounting for other factors. Importantly, the blood sugar differences between the two groups appeared to even out by 5 years, suggesting the glycemic disadvantage may be temporary.
This research suggests that the cardiovascular benefits of statin therapy in people newly diagnosed with type 2 diabetes appear to outweigh the adverse effects on blood sugar control, but that clinicians and patients should be aware that closer monitoring of blood sugar and potentially more aggressive diabetes treatment may be needed when statins are started. The findings reinforce current guidelines recommending statins for cardiovascular protection in people with diabetes, while highlighting the importance of vigilant blood sugar management in this population.
Ran Y, Jiang L, Ran J, Zhu Y, Pan L, Yang B, et al.. (2026). Effects of statins on glycemic control and cardiovascular events in patients with new-onset type 2 diabetes: a retrospective cohort study.. Frontiers in endocrinology. https://doi.org/10.3389/fendo.2026.1921249